Curacyte: Picking the best research
When Curacyte AG was founded in 2000, the company did not have a clear-cut technology or therapeutic focus. It had platforms in cancer and immunology and said it was developing therapies in cancer, immunodysregulation and thrombocytopenia, among others. Today, Curacyte has a lead in Phase III and another awaiting the start of clinical trials. In addition, the research pipeline has six compounds, four of them about to reach the preclinical stage.
CEO Helmut Giersiefen, a former project director at Roche (SWX:ROCZ, Basel, Switzerland), attributes the company's pace to its decision not to rely on genomics for drug discovery and not to do high throughput screening to generate leads. Instead, the company is screening the output of Germany's leading research institutions...